Gossamer Bio, Inc.
$0.42
▲
1.37%
2026-04-21 07:09:01
www.gossamerbio.com
NMS: GOSS
Explore Gossamer Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$98.57 M
Current Price
$0.42
52W High / Low
$3.87 / $0.32
Stock P/E
—
Book Value
$-0.53
Dividend Yield
—
ROCE
-150.03%
ROE
365.33%
Face Value
—
EPS
$-0.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
161
Beta
2.16
Debt / Equity
-1.65
Current Ratio
2.64
Quick Ratio
2.64
Forward P/E
-2.45
Price / Sales
1.98
Enterprise Value
$162.08 M
EV / EBITDA
-0.99
EV / Revenue
3.34
Rating
Hold
Target Price
$3.69
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PTC Therapeutics, Inc. | $72.32 | 8.72 | $5.95 B | — | 44.37% | -104.75% | $87.5 / $35.95 | $-2.52 |
| 2. | SAB Biotherapeutics, Inc. | $3.86 | 14.78 | $196.16 M | — | -30.19% | 14.96% | $6.6 / $1.3 | $3.18 |
| 3. | Omeros Corporation | $13.47 | — | $997.87 M | — | -49.6% | 2.21% | $17.65 / $2.95 | $-1.69 |
| 4. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
| 5. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 6. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 7. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.8 M | 13.29 M | 11.49 M | 9.89 M | 9.38 M | — |
| Operating Profit | -46.04 M | -41.64 M | -38.77 M | -36.81 M | -36.13 M | — |
| Net Profit | -47.24 M | -48.22 M | -38.27 M | -36.64 M | -33.03 M | — |
| EPS in Rs | -0.2 | -0.21 | -0.16 | -0.16 | -0.14 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 48.47 M | 114.7 M | 0 M | 0 M |
| Operating Profit | -163.25 M | -59.92 M | -173.76 M | -218.53 M |
| Net Profit | -170.37 M | -56.53 M | -179.82 M | -229.38 M |
| EPS in Rs | -0.73 | -0.24 | -0.77 | -0.98 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 172.25 M | 315.29 M | 311.92 M | 272.45 M |
| Total Liabilities | 295.01 M | 285.8 M | 249.15 M | 260.37 M |
| Equity | -122.76 M | 29.49 M | 62.77 M | 12.08 M |
| Current Assets | 167.64 M | 309.89 M | 306.52 M | 261.88 M |
| Current Liabilities | 63.44 M | 45.01 M | 51.6 M | 49.23 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -171.27 M | -3.47 M | -159.16 M | -187.03 M |
| Investing CF | 156.36 M | 29.02 M | -110.97 M | -1.03 M |
| Financing CF | 6.42 M | -11.49 M | 190.15 M | 117.09 M |
| Free CF | -171.34 M | -3.47 M | -159.16 M | -187.51 M |
| Capex | -0.08 M | — | — | -0.47 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 68.56% | 21.61% | — | — |
| Profit Margin % | -49.28% | — | — | — |
| Operating Margin % | -52.24% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -34.84% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.